Umemoto, Seiji
,
Ogihara, Toshio
Matsuzaki, Masunori
Rakugi, Hiromi
Ohashi, Yasuo
Saruta, Takao
Article History
Received: 31 July 2016
Revised: 2 October 2016
Accepted: 5 October 2016
First Online: 1 December 2016
Competing interests
: Dr SU was supported by research grants from Yamaguchi Prefecture, Japan, and KHK. Dr HR was supported by research grants from Daiichi Sankyo, Astellas Pharma, Dainippon Sumitomo Pharma, Eisai, Kowa Pharmaceutical, Mitsubishi Tanabe Pharma, Mochida Pharmaceutical, MSD, Nippon Boehringer Ingelheim, Novartis Pharma, Otsuka Pharmaceutical, Pfizer Japan, Sanofi, Shionogi and Takeda Pharmaceutical. Dr SU received honoraria from Boehringer Ingelheim, Mochida Pharmaceutical, Takeda Pharmaceutical, Kowa Pharmaceutical, Novartis Pharma, Bayer Yakuhin and Daiichi Sankyo. Dr HR received honoraria from KHK, Astellas Pharma, Daiichi Sankyo, Dainippon Sumitomo Pharma, Takeda Pharmaceutical, Eisai, Mitsubishi Tanabe Pharma, Mochida Pharmaceutical, MSD, Nippon Boehringer Ingelheim, Novartis Pharma, Pfizer Japan, Shionogi, Taisho Toyama Pharmaceutical, and Bayer Yakuhin. Dr SU serves on an ad-hoc advisory board for Nippon Boehringer Ingelheim. The remaining authors declare no conflict of interest.